Research Papers:

Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac

Yoko Goto _, Ryo Ashida, Akira Nakamura, Satoshi Itasaka, Keiko Shibuya, Mami Akimoto, Nobutaka Mukumoto, Shigemi Matsumoto, Masashi Kanai, Hiroyoshi Isoda, Toshihiko Masui, Yuzo Kodama, Mitsuhiro Nakamura, Kyoichi Takaori, Takashi Mizowaki and Masahiro Hiraoka

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:23628-23635. https://doi.org/10.18632/oncotarget.25310

Metrics: PDF 1387 views  |   HTML 1822 views  |   ?  


Yoko Goto1, Ryo Ashida1, Akira Nakamura1, Satoshi Itasaka1, Keiko Shibuya2, Mami Akimoto1, Nobutaka Mukumoto1, Shigemi Matsumoto3, Masashi Kanai3, Hiroyoshi Isoda4, Toshihiko Masui5, Yuzo Kodama6, Mitsuhiro Nakamura1, Kyoichi Takaori5, Takashi Mizowaki1 and Masahiro Hiraoka1,7

1Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan

2Department of Radiation Oncology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan

3Department of Clinical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

4Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

5Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

6Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

7Department of Radiation Oncology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan

Correspondence to:

Yoko Goto, email: [email protected]

Keywords: dynamic tumor tracking (DTT); intensity-modulated radiotherapy (IMRT); chemoradiotherapy; locally advanced pancreatic cancer; prognosis

Received: January 05, 2018     Accepted: April 14, 2018     Published: May 04, 2018


Objectives: We performed dynamic tumor-tracking IMRT (DTT-IMRT) in locally advanced pancreatic cancer (LAPC) patients using a gimbaled linac of Vero4DRT. The purpose of this study is to report the first clinical results.

Methods: From June 2013 to June 2015, eleven LAPC patients enrolled in this study and DTT-IMRT was successfully performed. The locoregional progression free survival (LRPFS), distant metastasis free survival (DMFS), overall survival (OS), hematologic and gastrointestinal (GI) toxicities were evaluated. Oncologic outcomes were estimated using Kaplan-Meier analysis, and toxicities using CTCAE v4.0.

Results: The median radiation dose was 48 Gy (range, 45-51) in 15 fractions. Concurrent chemoradiotherapy (CCRT) was performed using gemcitabine in 9 patients and S-1 in one, while one patient refused. With a median follow-up of 22.9 months, 1-year LRPFS, DMFS, and OS rates were 90.9%, 70.7%, and 100%, respectively. Median survival time was 23.6 months. Grade-3 leucopenia and neutropenia were observed in two (18%) and one patient (9%), respectively. Grade-2 acute GI toxicity occurred in 2 patients (18%) and late grade-3 in 1 patient (9%).

Conclusions: Preliminarily application of DTT-IMRT using a gimbaled linac on CCRT in LAPC patients resulted in excellent locoregional control and OS without severe toxicity.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25310